Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: May 3, 2011


Illumina has tapped Kevin Williams to be its new senior director of investor relations, a position he will take over incrementally over the coming quarter from Peter Fromen. Fromen will move into a new position at Illumina as senior director of applications marketing.

Prior to joining Illumina, Fromen was the director of investor relations at Applied Biosystems. He has held finance and investor relations roles at Agilent Technologies, and was an equity research anaylst and associate portfolio manager at Howard Capital Management.

SynapDx said last week that Thomas Mac Mahon has joined its board of directors.

Mac Mahon was previously president and CEO and a member of Laboratory Corporation of America from 1997 until his retirement at the end of 2006. Prior to LabCorp, Mac Mahon was senior vice president of Roche from 1993 to 1996 and president of Roche Diagnostics Group from 1988 to 1996.

He is currently a director of Express Scripts and a member of the board of PharMerica.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.